Evidence map›Paper›PMID 25425964›Full record

ArticleNeoplasia (New York, N.Y.)2014

The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc.

John R Prensner, Wei Chen, Sumin Han, Matthew K Iyer, Qi Cao, Vishal Kothari, Joseph R Evans, Karen E Knudsen, Michelle T Paulsen, Mats Ljungman and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neoplasia (New York, N.Y.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 154 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
154citing papers in PubMed, 3 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

154 citing papers in PubMed, 3 syntheses or guidelines pooled it, 253 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. LncRNA expression in prostate cancer: FromNon-coding RNA research · 2026
    Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Involvement of lncRNA in cancer diagnosis and prognosis and clinical implications.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

94 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

John R PrensnerMichigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Wei ChenDepartment of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI, USA.
Sumin HanDepartment of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI, USA.
Matthew K IyerMichigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Qi CaoMichigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI, USA ; Department of Pathology, University of Michigan Medical School,Ann Arbor, MI, USA.
Vishal KothariDepartment of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI, USA.
Joseph R EvansDepartment of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI, USA.
Karen E KnudsenDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA ; Department of Urology, Thomas Jefferson University, Philadelphia, PA, USA ; Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA.
Michelle T PaulsenDepartment of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI, USA ; Translational Oncology Program, University of Michigan Medical School, Ann Arbor, MI, USA.
Mats LjungmanDepartment of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI, USA ; Translational Oncology Program, University of Michigan Medical School, Ann Arbor, MI, USA.
Theodore S LawrenceDepartment of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI, USA.
Arul M ChinnaiyanMichigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI, USA ; Department of Pathology, University of Michigan Medical School,Ann Arbor, MI, USA ; Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA ; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA ; Howard Hughes Medical Institute, University of Michigan Medical School, Ann Arbor, MI, USA.
Felix Y FengMichigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI, USA ; Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI, USA ; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA.
University of Michigan–Ann Arbor · USMichigan Center for Translational Pathology · USThomas Jefferson University · US

Funding

MICHIGAN MEDICAL SCIENTIST TRAINING PROGRAMT32GM007863 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COLLINS, KATHLEEN L. · 1985 to 2024
$38.3M
VACCINIA PSA FOR ANDROGEN-MODULATED POST-SURGICAL RECURRENCE OF PROSTATE CANCERP50CA069568 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COONEY, KATHLEEN A · 1995 to 2013
$31.3M
Tissue/InformaticsP50CA186786 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Robert Timothy Dess · 2014 to 2026
$27.6M
Epitomic Biomarkers of Prostate CancerU01CA111275 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M, RUBIN, MARK A. · 2004 to 2015
$6.8M
Molecuar Sub-typing of Prostate Cancer Based on Recurrent Gene FusionsR01CA132874 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M · 2009 to 2013
$1.2M
NCI NIH HHS P50 CA069568NCI NIH HHS P50 CA186786NCI NIH HHS P50CA69568NCI NIH HHS PC094231NCI NIH HHS R01 CA132874NCI NIH HHS R01CA132874-01A1NCI NIH HHS U01 CA111275NIGMS NIH HHS T32 GM007863
6 · The paper itself

Abstract

Long non-coding RNAs (lncRNAs) represent an emerging layer of cancer biology, contributing to tumor proliferation, invasion, and metastasis. Here, we describe a role for the oncogenic lncRNA PCAT-1 in prostate cancer proliferation through cMyc. We find that PCAT-1-mediated proliferation is dependent on cMyc protein stabilization, and using expression profiling, we observed that cMyc is required for a subset of PCAT-1-induced expression changes. The PCAT-1-cMyc relationship is mediated through the post-transcriptional activity of the MYC 3' untranslated region, and we characterize a role for PCAT-1 in the disruption of MYC-targeting microRNAs. To further elucidate a role for post-transcriptional regulation, we demonstrate that targeting PCAT-1 with miR-3667-3p, which does not target MYC, is able to reverse the stabilization of cMyc by PCAT-1. This work establishes a basis for the oncogenic role of PCAT-1 in cancer cell proliferation and is the first study to implicate lncRNAs in the regulation of cMyc in prostate cancer.

Indexed as

3' Untranslated RegionsCell Line, TumorCell ProliferationGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMicroRNAsOligonucleotide Array Sequence AnalysisProstatic NeoplasmsProto-Oncogene Proteins c-mycReverse Transcriptase Polymerase Chain ReactionRNA InterferenceRNA, Long Noncoding3' Untranslated RegionsMicroRNAsMYC protein, humanPCAT-1 lncRNA, humanProto-Oncogene Proteins c-mycRNA, Long Noncoding3’UTRcell proliferationcMyclncRNAPCAT-1

Identifiers

PMID25425964
PMCPMC4240923
OpenAlexW2153248764

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.